Ongoing research is focusing on these issues, and it is widely agreed that additional in vivo investigations, particularly studies on chronic exposure and reproductive toxicity, are required to confidently establish comprehensive safety profiles (209, 214)
Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
Sustained Foxp3 upregulation constitutes a signature trait of Treg cells [59]
S6 STIMULANTS In competition All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances
Additionally, in order to explore the mechanism of action being neuronal apoptosis, the research team assessed levels of neuroinflammation and glial activation by detecting levels of IL-1-beta, IL-10, and TNF-alpha in the brain
